# Centene Corporation account plan

> Centene is a St. Louis managed care company focused on underserved populations, with $194.8 billion of 2025 revenue and 25.9 million members in June 2026.

## At a glance

Centene, headquartered in St. Louis and listed on the NYSE as CNC, runs government-sponsored and commercial health plans through state-based subsidiaries with local brands. It is the largest Medicaid and Marketplace insurer and the largest stand-alone Medicare prescription drug plan provider in the U.S. In FY2025 total revenues were $194.8 billion (+19%), but a $6.7 billion non-cash goodwill impairment led to a net loss attributable to Centene of $(6,674) million; adjusted diluted EPS was $2.08. Membership was 27.6 million at December 31, 2025, served by approximately 61,100 team members.

## Business units

- **Medicaid** (57% of 2025 external revenues ($110,434 million total revenues)): State Medicaid programmes including TANF, Expansion, Aged/Blind/Disabled, CHIP and long-term services, with 12.5 million members in 30 states at end-2025, the largest Medicaid insurer in the U.S. Margins were hit in 2025 by behavioral health, home health and high-cost drug costs; Q2 2026 gross margin rose 24% on rate increases and cost management.
- **Commercial** (21% of 2025 external revenues ($42,003 million total revenues)): The Ambetter Health Marketplace product, the largest Marketplace carrier with 5.5 million members across 29 states at end-2025, plus ICHRA and other off-exchange plans. After a $2.6 billion gross margin drop in 2025, repricing lifted Q2 2026 gross margin to $1,947 million while Marketplace membership fell to 3,494,700.
- **Medicare** (19% of 2025 external revenues ($37,210 million total revenues)): Wellcare Medicare Advantage, with 1.0 million members in 32 states and a high concentration of D-SNP dual-eligible members, and the country's largest stand-alone PDP, with 8.1 million members at end-2025. Medicare Advantage is targeted at breakeven or better in 2027.
- **Other** (3% of 2025 external revenues ($5,130 million total revenues)): AcariaHealth specialty pharmacy, Magellan Health behavioral health (remaining businesses to be divested), vision and dental programmes, and clinical care through Community Medical Group and Denova Collaborative Health.

## Strategic priorities

- **Margin restoration**: Corrective 2026 Marketplace pricing in states covering 95% of membership, Medicaid rates matched to post-redetermination acuity, and medical cost management including fraud, waste and abuse detection.
- **Dual-eligible integration**: Centene will "place enterprise-level focus on the D-SNP opportunity to drive long-term growth"; D-SNP members are about 40% of Medicare Advantage, and new integrated duals contracts began in Illinois, Ohio and Michigan in January 2026.
- **Industry-leading cost structure**: Enterprise optimization simplifies the organisation and operating model through digitisation, AI and voluntary buyouts, with an estimated $480 million midpoint of related SG&A costs in 2026.
- **AI on trusted data foundations**: AI work is shifting from use cases to trusted data products, context management and open standards under a strict ROI bar, and finance uses analytics and AI in forecasting, medical economics and payment integrity.
- **ICHRA and value-based care**: ICHRA plans expanded from 6 to 13 states in 2026 and reached roughly 50,000 members, and providers are being moved toward shared and full risk arrangements.

## Latest results

In Q2 2026 total revenues rose 10% to $53.6 billion and premium and service revenues 4% to $44.4 billion. The health benefits ratio improved to 89.6% from 93.0%, helped by better Marketplace pricing and risk adjustment, Medicaid rate increases and cost management; GAAP diluted EPS was $2.19 and adjusted diluted EPS $2.51. Membership fell 8% year on year to 25.9 million, mainly in the Marketplace. Full-year 2026 adjusted EPS guidance was raised to greater than $4.80 from greater than $3.40, though about $0.50 of Q2 earnings came from 2025 settlements not expected to recur in 2027.

## Investments and deals

- **Systems capex**: Capex was $767 million in 2025; about $800 million is expected in 2026, mainly system enhancements and computer hardware and software.
- **Deleveraging**: $1.3 billion of senior notes were repurchased in H1 2026, partly funded by selling a $1.0 billion interest in 2025 Part D receivables; debt-to-capital fell to 41.6% from 46.5%.
- **Magellan Health divestiture**: A definitive agreement to divest the remaining Magellan Health businesses was signed in December 2025, after a $513 million impairment.
- **Voluntary separation program**: Accepted on July 27, 2026, with about $315 million to $365 million of severance expected over the rest of 2026.

## Challenges and risks

- **Medicaid policy changes**: The One Big Beautiful Bill Act brings Medicaid work requirements and more frequent redeterminations largely from 2027; Medicaid membership is expected down 8% to 9% in 2026.
- **Marketplace membership and morbidity**: Expiry of enhanced Marketplace subsidies at end-2025 cut membership from 5,541,400 to 3,494,700 by June 2026 and raised the acuity of remaining members.
- **Medical cost trend**: Behavioral health remains the largest trend driver, with home health and high-cost drugs, and payment-integrity teams target "AI up-coding".
- **Contract losses**: Centene was not selected for Florida Children's Medical Services, its Hawaii Medicaid contracts were not renewed, and about 250,000 California Medi-Cal members leave managed care on January 1, 2027.

## What leadership says

> "delivering industry-leading health outcomes with an industry-leading cost structure." — Sarah London, Chief Executive Officer, Q2 2026 earnings call, July 29, 2026

> "We aren't just going to deploy AI to talk about AI." — Sarah London, Chief Executive Officer, Q2 2026 earnings call, July 29, 2026

> "this work is not about self-regulating, it's about self disrupting." — Sarah London, Chief Executive Officer, Q1 2026 earnings call, April 28, 2026, on prior authorization commitments

> "They saw and called a market-wide issue first." — Sarah London, Chief Executive Officer, Q2 2026 earnings call, July 29, 2026, on the Marketplace team


## Where a supplier can help

- **AI with measurable ROI**: Centene is building trusted data products and holds AI to a strict ROI bar; vendors with proven savings in claims, legal or administrative work fit the enterprise optimization priority.
- **Payment integrity and fraud detection**: Medical cost management relies on catching inappropriate billing before payment, including AI up-coding, which suits payment-integrity and analytics providers.
- **Eligibility and work-requirement support**: OBBBA work requirements and redeterminations push Centene to exchange near real-time data with states and run workforce playbooks, where eligibility, data exchange and community engagement partners can help.
- **Dual-eligible care programmes**: The D-SNP focus calls for care coordination, member engagement and value-based care partners in oncology, kidney disease and behavioral health.
- **System modernisation**: About $800 million of 2026 capex goes to system enhancements and hardware and software, alongside digitisation under enterprise optimization.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Centene Annual Report on Form 10-K, fiscal year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/1071739/000107173926000049/cnc-20251231.htm)

Annual report · 2026-02-17

- Centene (St. Louis, NYSE: CNC) calls itself "the nation's largest managed care company focused on underserved populations": the largest Medicaid and Marketplace insurer and the largest stand-alone Medicare prescription drug plan (PDP) provider. Membership 27.6 million at December 31, 2025; approximately 61,100 team members.
- FY2025 total revenues $194.8 billion (+19%), premium and service revenues $174.6 billion (+20%); health benefits ratio (HBR) 91.9% vs 88.3%; SG&A ratio 7.4% vs 8.5%; operating cash flow $5.1 billion.
- A hard year: a $6.7 billion non-cash goodwill impairment drove a GAAP diluted loss per share of $(13.53); adjusted diluted EPS $2.08 vs $7.17 in 2024.
- Four segments by share of external revenues: Medicaid 57% (12.5 million members in 30 states), Commercial 21% (Ambetter Health Marketplace, 5.5 million members in 29 states), Medicare 19% (Wellcare: 1.0 million Medicare Advantage members in 32 states, 8.1 million PDP members) and Other 3% (AcariaHealth specialty pharmacy, Magellan Health, vision and dental, clinical care).
- 2025 pressure points: lower Marketplace risk adjustment revenue after data showed "significantly higher estimated aggregate market morbidity", plus higher Medicaid costs in behavioral health, home health and high-cost drugs; Commercial gross margin fell $2.6 billion.
- Responses: corrective 2026 Marketplace pricing in states covering 95% of membership; Medicare Advantage refocused on D-SNP duals (membership down 10%); ICHRA off-exchange plans expanded from 6 to 13 states in 2026; remaining Magellan Health businesses to be divested ($513 million impairment).
- Policy headwinds: the One Big Beautiful Bill Act (Medicaid work requirements and more frequent redeterminations largely from 2027, provider-tax and state-directed-payment changes from 2028), expiry of enhanced Marketplace subsidies at end-2025, IRA changes to Part D.
- 2026 expectations in the filing: about $800 million of capex (system enhancements, hardware and software) and about $1.2 billion of net dividends from regulated subsidiaries; debt-to-capital 46.5%; $1.8 billion left on the buyback authorisation.

### [Centene Quarterly Report on Form 10-Q for Q2 2026 (quarter ended June 30, 2026)](https://www.sec.gov/Archives/edgar/data/1071739/000107173926000153/cnc-20260630.htm)

Interim report · 2026-07-28

- Q2 2026 total revenues $53.6 billion (+10%), premium and service revenues $44.4 billion (+4%); HBR 89.6% vs 93.0%; adjusted SG&A ratio 6.9% vs 7.1%.
- GAAP diluted EPS $2.19 (vs a $(0.51) loss in Q2 2025) and adjusted diluted EPS $2.51; first-half GAAP diluted EPS $5.30.
- Managed care membership 25.9 million, down 2.1 million (8%) year on year: Medicaid 12,110,700, Marketplace 3,494,700 (from 5,862,800), PDP 8,803,000, Medicare 980,000.
- Commercial gross margin more than doubled to $1,947 million on repricing and risk adjustment; final 2025 Marketplace risk adjustment gave a $481 million pre-tax benefit. Medicare gross margin +35%, Medicaid +24%.
- Enterprise optimization: a voluntary separation program accepted July 27, 2026, with about $315 million to $365 million of severance expected over the rest of 2026.
- Deleveraging: $1.3 billion of senior notes repurchased in H1 (partly funded by selling $1.0 billion of 2025 Part D receivables); debt-to-capital down to 41.6% from 46.5%.
- Upcoming headwinds: about 250,000 California Medi-Cal UIS members leave managed care on January 1, 2027; Hawaii Medicaid contracts not renewed; Florida CMS contract ends September 2026. Wins: Illinois HealthChoice Medicaid contract from January 2027.

### [Centene Q2 2026 earnings call transcript (Sarah London, CEO; Drew Asher, CFO)](https://www.mitrade.com/insights/news/live-news/article-8-1941442-20260729)

Executive talk · Sarah London, Chief Executive Officer · 2026-07-29

- London framed Q2 as progress on "margin restoration": adjusted EPS $2.51 beat expectations and full-year 2026 adjusted EPS guidance rose to greater than $4.80 from greater than $3.40; Asher flagged about $0.50 of 2025 settlements that will not recur in 2027.
- Marketplace (Ambetter) is the swing factor: HBR 79.2% vs 90.6%; pretax margin now expected at 4.5% to 5% (prior 3%), after the June Wakely data confirmed higher-acuity Silver members and $180 million of favourable 2025 risk adjustment.
- Medicaid on plan at a 93.9% Q2 HBR, full-year target about 93.5%; 2026 composite rate now about 5% (from 4.5%); membership expected down 8% to 9% for the year as states tighten eligibility ahead of OBBBA ("OB3") work requirements.
- Medicare: PDP pretax margin now greater than 3% (guided 2%) on about $25 billion of premium revenue; D-SNP is about 40% of Medicare Advantage; MA targeted at "breakeven or better results in 2027", with a simplified 2027 footprint focused on duals.
- Pharmacy scale: more than $60 billion of pharmacy spend leveraged through the partnership with ESI.
- Enterprise optimization: organisation simplification, voluntary buyouts, about $480 million midpoint of related SG&A costs in 2026; ambition of "industry-leading health outcomes with an industry-leading cost structure".
- AI: shifting from use cases to foundations (trusted data products, context management, open standards) with a strict ROI bar; a legal-invoice review agent saves 1.5 points on legal bills.
- ICHRA about 50,000 members, 2.5x a year earlier.

### [Centene Q1 2026 earnings call transcript (Sarah London, CEO; Drew Asher, CFO)](https://bullfincher.io/companies/centene-corporation/earnings-call/fy2026-q1)

Executive talk · Sarah London, Chief Executive Officer · 2026-04-28

- Q1 2026 adjusted diluted EPS $3.37 beat plan; full-year adjusted EPS guidance raised to greater than $3.40 from greater than $3, with a "prudent outlook" for the rest of the year.
- Medicaid HBR 93.1% (50 basis points better year on year), third consecutive quarter of progress; net trend assumed mid-4% and composite rate yield about 4.5%; ABA trends stabilising after fraud, waste and abuse work.
- Medicare HBR 84.9%, both Medicare Advantage and PDP ahead; D-SNP members now 40% of MA; path to MA breakeven in 2027; PDP ended Q1 with just over 8.7 million members.
- Marketplace: just under 3.6 million members (about half Silver, roughly 35% Bronze); higher Silver utilisation expected to earn a risk adjustment offset; pretax margin guided around 3% pending June Wakely data. Centene initiated an earlier industry demographic report with Wakely.
- New leadership structure: Dan Finke joined as Group President for Medicaid and Commercial; Michael Carson elevated to Group President for Medicare, PDP and Specialty.
- Balance sheet: $1 billion of 2025 Part D receivables sold to repurchase $1 billion of notes; debt-to-capital 43.2%; operating cash flow $4.4 billion.
- RFP pipeline: a lighter procurement year, but states (e.g. Indiana) consolidating reprocurements and considering carving higher-acuity populations into managed care.

## Questions about Centene Corporation

### What does Centene do?

Centene is a managed care company focused on underserved populations. It runs Medicaid, Marketplace (Ambetter Health) and Medicare (Wellcare and stand-alone drug plans) health plans through state-based subsidiaries.

### What is Centene's revenue?

Total revenues were $194.8 billion in FY2025, up 19%. In Q2 2026 total revenues were $53.6 billion, up 10%.

### How many employees and members does Centene have?

Centene had approximately 61,100 team members and 27.6 million members at December 31, 2025; membership was 25.9 million at June 30, 2026.

### What is Centene's strategy?

It is restoring margins through repricing and medical cost management, focusing Medicare on dual-eligible D-SNP members, simplifying the organisation, and growing ICHRA products.

### Who leads Centene?

Sarah M. London has been CEO since March 2022, with Andrew L. Asher as EVP and CFO and Susan R. Smith as COO.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
